Bosentan and Sildenafil in Pulmonary Hypertension in Cardiac Anesthesia

Bosentan and Sildenafil in Pulmonary Hypertension in Cardiac Anesthesia: Mansoura Novel Strategy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202209903019732

Enrollment

Registered

2022-09-02

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Cardiology Anaesthesia

Interventions

S group Sildenafil group

SB group Sildenafil plus bosentan group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.American Society of Anesthesiologists physical status grade II and ?. 2.Age between 20 and 70 years. 3.either gender. 4.Systolic pulmonary artery pressure greater than 70 mmHg.

Exclusion criteria

Exclusion criteria: 1.Patient refusal. 2.Uncompensated cardiac disease. 3.Severe chronic obstructive pulmonary disease ( COPD) and bronchial asthma. 4.Chest infection. 5.uncontrolled HTN and DM. 6.Preoperative liver and renal disease. 7.Body Mass Index > 40 Kg/m2. 8.Hematologic disorders. 9.Neuromuscular disorders. Redo and urgent surgeries.

Design outcomes

Primary

Measure	Time frame
Systolic Pulmonary artery pressure, Pulmonary vascular resistance, Tricuspid annular plane systolic excursion (TAPSE),	—

Secondary

Measure	Time frame
Heart rate, MAP, pulse oximetry Cross Clamp time., Bypass time. Anaesthesia time.Duration of surgery. Vaso-active inotropic medications;CRP, RBG laboratory assessment	—

Countries

Egypt

Contacts

Public ContactOla Taha ;Naglaa Abdeldayem;Abdelatief ElNegeery

Ola T. Abdeldayem;Elnegeery N.A.

olataha2007@yahoo.com;naglaaelnegeery@gmail.com00201202811110;02001006198288

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026